Early heart attack therapy with bone marrow extract improves cardiac functionJune 30, 2009A UCSF study for the treatment of heart failure after heart attack found that the extract derived from bone marrow cells is as effective as therapy using bone marrow stem cells for improving cardiac function, decreasing the formation of scar tissue and improving cardiac pumping capacity after heart attack. Findings were published online and in the July 2009 issue of the Journal of Molecular Therapy. The cover of the journal features a microscope image of cells from the UCSF study. The studies were done in mice using a novel stem cell delivery method developed by UCSF researchers to show that the extract from bone marrow cells is as beneficial to cardiac function as are intact, whole cells. Both the cell and cell extract therapies resulted in the presence of more blood vessels and less cardiac cell death, or apoptosis, than no therapy. The study also showed that heart function benefitted despite the finding that few of the injected cells remained in the heart at one month after therapy. "Peer-reviewed medical literature is controversial as to whether bone marrow cells differentiate into cardiomyocytes, or cardiac muscle cells, but there is general agreement that stem cell therapy with these cells results in some level of functional improvement after a heart attack. The exact mechanism for this is not yet clear. Our results confirm that whole cells are not necessarily required in order to see the beneficial effects of bone marrow cell therapy," said Yerem Yeghiazarians, MD, study author, cardiologist and director of UCSF's Translational Cardiac Stem Cell Development Program. UCSF researchers are investigating these new therapies to improve cardiac function after heart attack in an effort to prevent heart failure. Heart failure occurs when cardiac muscle is damaged and scar tissue replaces beating cardiomyocytes. As scar replaces healthy tissue, it causes the heart to enlarge and lose its pumping capacity. When the pumping capacity decreases, the heart fills with fluid, which moves to the lungs and can lead to organ failure and death. "Current therapies improve symptoms but do not replace scar tissue. Our hope is to use stem cells to decrease the scar, minimize the loss of cardiac muscle and maintain or even improve the cardiac function after a heart attack," Yeghiazarians said. Using a novel, closed-chest, ultrasound-guided injection technique developed by Yeghiazarians and his colleagues, the team administered three different groups with bone marrow cells, bone marrow cell extract, or saline (for the control group). The injections were administered at day three after heart attack - a timeframe somewhat similar to human biology on days six-to-seven after heart attack. The team found at day 28 that both the bone marrow cell group and the extract group had significantly smaller heart damage than the control group. Left-ventricular ejection fraction (LVEF), or the measurement of blood pumped out of the ventricles per heart beat, fell uniformly in each group after heart attack from a level of about 57.2 percent to 38.4 percent. At day 28 (and after the therapies had been administered on day three), LVEF improved in both the bone marrow cell and extract groups to approximately 40.6 and 39.1 percent as compared to approximately 33.2 percent for the control group. "We hope our findings can help in the development of new therapies for improving heart function after the deleterious effects of a heart attack," says Yeghiazarians. The team is continuing to evaluate bone marrow cell and extract therapies in order to identify the proteins and factors within the extract and gain insight into the possible mechanisms of cardiac functional improvement. "The best acute therapy for a heart attack remains early recognition and revascularization of the blocked artery to minimize the damage to the heart muscle," said Yeghiazarians. "Although the prognosis depends on multiple factors, what we know for sure is that the sooner a heart attack gets diagnosed and cardiologists open the blocked artery, the better the long-term outcome. There are a number of ongoing stem cell-based clinical trials, and depending on further research and the outcome of these studies, we might have new therapies for the treatment of patients who suffer from a heart attack in the not-too-distant future." University of California - San Francisco |
|||||||||||||||||||||
| Related Heart Attack Current Events and Heart Attack News Articles Inhibition of GRK2 is protective against acute cardiac stress injuries Inhibition of a protein known to contribute to heart failure also appears to be protective of the heart in more acute cardiac stress injury, namely ischemia reperfusion. Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. Heart and bone damage from low vitamin D tied to declines in sex hormones Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone. Elevated biomarkers lead to diminished quality of life in heart attack patients post-discharge Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study. Tiny particles can deliver antioxidant enzyme to injured heart cells Researchers at Emory University and the Georgia Institute of Technology have developed microscopic polymer beads that can deliver an antioxidant enzyme made naturally by the body into the heart. Early end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. oo much selenium can increase your cholesterol A new study from the University of Warwick has discovered taking too much of the essential mineral selenium in your diet can increase your cholesterol by almost 10%. Higher carotid arterial stenting rates associated with poorer clinical outcomes Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine. Study suggests dentists can identify patients at risk for fatal cardiovascular event A new study indicates dentists can play a potentially life-saving role in health care by identifying patients at risk of fatal heart attacks and referring them to physicians for further evaluation. Common Pain Relievers May Dilute Power of Flu Shots With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. More Heart Attack Current Events and Heart Attack News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||